Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species - Wikidata - wikimedia - TriplyDB

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

http://www.wikidata.org/entity/Q34680546

about

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa Three decades of beta-lactamase inhibitors Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae The continuing challenge of ESBLs.Pharmacokinetic evaluation of piperacillin-tazobactam.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Evolution of β-lactams resistance in Gram-negative bacteria in Tunisia.Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.β-lactam/β-lactamase inhibitor combinations: from then to now.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

P2860

Q24612271-965E6D28-10F8-4577-BEF6-244539E8FBE4 Q24646623-AAB89441-7D9F-4A44-B182-AB3278C36C2A Q30396308-745291A7-C95B-4512-A4D1-2DE29354EDF5 Q33776486-8790CA0D-A35C-42CC-9355-489F1631B540 Q35666617-DD45027D-DF40-4707-8CA8-50A5359914C3 Q35840852-9D55C609-AEFE-4BA7-9F61-15D55E010B3C Q36095794-650AA8D1-6574-49A9-B871-BD2D5D6B692F Q36449603-5C1C385B-B11F-41D7-92CC-8DBA5F71E18C Q37773368-0FB6D127-3765-4B38-959B-87EE2C2657D1 Q37838117-3182BFA1-EF1E-40E2-B46D-55986F49E4AD Q37857875-AF522BEB-19CF-474F-8322-D259E566D3BF Q38078878-481602FE-B46D-45BD-9384-036AB603F192 Q38165138-5361152B-A7C5-4B6C-BF3F-F0C5EA27A546 Q38264182-806F61B7-5AB4-4E2C-B07D-9F53B00595DE Q38286351-C8AD7A6D-BA78-4CE0-B02C-F13592882861 Q38401630-5833429F-5F3B-407D-BE02-BC3D3579D0E1 Q38739545-3F038358-D8C1-47B1-808C-B643AD07BD5F Q38864569-7947BE4C-A906-45DE-B3DB-4CE04BD7E6B8 Q40922179-9DA6205C-42B9-4332-B2E6-B68B0C43690E Q41440864-D84AE62F-68E4-4911-A874-4033DF971180 Q47315442-CFD4E626-27D4-46F8-8867-F69B72739FE6 Q54389084-9CB9797A-C4EF-4D54-82BE-7429952D2976

P2860

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species

http://www.wikidata.org/entity/Q34680546

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Clinical correlation of the CL ...... ia coli and Klebsiella species

@ast

Clinical correlation of the CL ...... ia coli and Klebsiella species

@en

Clinical correlation of the CL ...... ia coli and Klebsiella species

@nl

type

label

Clinical correlation of the CL ...... ia coli and Klebsiella species

@ast

Clinical correlation of the CL ...... ia coli and Klebsiella species

@en

Clinical correlation of the CL ...... ia coli and Klebsiella species

@nl

prefLabel

Clinical correlation of the CL ...... ia coli and Klebsiella species

@ast

Clinical correlation of the CL ...... ia coli and Klebsiella species

@en

Clinical correlation of the CL ...... ia coli and Klebsiella species

@nl

P1433

Q34680546-611931C4-17A7-464B-9247-D8CCCBABBD1F

P1476

Q34680546-2DC8CD1F-3056-4089-A463-C6A6F26DA0E0

P2093

Q34680546-061DBF6F-6C49-43B7-886B-8D08D1A461FB

Q34680546-17B1D08B-7AEB-4680-8F95-2B2100BBA7AA

Q34680546-1E3547C5-114D-4F2A-B30C-D5172C99710C

Q34680546-21860134-CBB5-4D72-8F5E-BBD761D57E60

Q34680546-55817B57-5039-4BD3-AEB3-A5E14B6838A9

Q34680546-7D137D59-CFDD-4CA6-A1B1-71EEB30E5E8E

Q34680546-7E1B13F3-DBD9-454F-8783-CBD19F6D094D

Q34680546-B290DBF5-92AA-4D94-9A9C-DCF956E4A61C

Q34680546-D588585F-833E-4203-9FFE-5A7D0C603D8E

Q34680546-EBA9E01A-CFF9-4420-9B73-C406C06AA2CB

P2860

Q34680546-00DBE997-68D3-421B-B660-679ADD725918

Q34680546-3EB766A2-51E5-49CB-8ACF-F318572BF721

Q34680546-423C3F61-4D58-4832-BD8A-E6B7842BA357

Q34680546-5B37F3D4-556F-4D97-BDC9-49865BEFE64A

Q34680546-5C875B1B-E028-4C30-8686-E9BB61BBE159

Q34680546-609F4343-34AB-4816-A7F7-DE43FD282FBD

Q34680546-6B0D4921-29B5-423C-8608-38A5E6A32480

Q34680546-78975D71-6EB3-47CE-A7DE-6366B140509C

Q34680546-78F02078-1C90-4217-97B4-735976102D46

Q34680546-7B0A0EF3-6045-4930-AF9F-FB8675ED9516

P304

Q34680546-83D43412-9FEB-4D71-A7C4-E2E009F612BD

P31

Q34680546-9F2D570A-B3F0-4716-8AA1-180129AD7562

P356

Q34680546-3BCB6BF6-CCED-4114-AC89-DFE63901123C

P407

Q34680546-E62DA542-FE03-402D-8826-BFE164819375

P433

Q34680546-15F0381A-C1E8-4DF2-B5DC-4D7F40C6CE03

P478

Q34680546-98397BA0-C6B5-4CCB-99DF-A3BE94C0E3F9

P577

Q34680546-02B2D09D-C11E-44D2-B63E-405A3A4BC9F7

P698

Q34680546-129DE9E3-68BA-4C32-982B-35323D87F5A9

P932

Q34680546-78CDB2B7-6642-44FC-A5B5-D6BEF506ADC0

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Clinical correlation of the CL ...... ia coli and Klebsiella species

@en

P2093

Carl L Pierson

http://www.w3.org/2001/XMLSchema#string

Coleman Rotstein

http://www.w3.org/2001/XMLSchema#string

Diane C Halstead

http://www.w3.org/2001/XMLSchema#string

J Michael Gaydos

http://www.w3.org/2001/XMLSchema#string

Jaber Aslanzadeh

http://www.w3.org/2001/XMLSchema#string

Lance R Peterson

http://www.w3.org/2001/XMLSchema#string

Mira T Suseno

http://www.w3.org/2001/XMLSchema#string

Patrick J Gavin

http://www.w3.org/2001/XMLSchema#string

Richard B Thomson

http://www.w3.org/2001/XMLSchema#string

Stephen Brecher

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

P304

2244-2247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00381-05

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16723596

http://www.w3.org/2001/XMLSchema#string

P932

1479103

http://www.w3.org/2001/XMLSchema#string